ECT2 phospho T790 Antibody

This antibody is designed, produced, and validated as part of a collaboration between Rockland and the National Cancer Institute (NCI) and is suitable for Cancer, Immunology and Nuclear Signaling research. ECT2, also known as epithelial cell transforming sequence 2 oncogene, was originally isolated as a transforming gene from epithelial cells. ECT2 catalyzes guanine nucleotide exchange on the small GTPases, RhoA, Rac1, and Cdc42. ECT2 may be phosphorylated during G₂ and M phases, and phosphorylation may be required for its exchange activity. Unlike other known guanine nucleotide exchange factors for Rho GTPases, ECT2 exhibits nuclear localization in interphase, spreads throughout the cytoplasm in prometaphase, and is condensed in the midbody during cytokinesis. Expression of dominant-negative ECT2 or microinjection of affinity-purified anti-ECT2 antibody into interphase cells strongly inhibits cytokinesis. These results suggest that ECT2 is an important link between the cell cycle machinery and Rho signaling pathways involved in the regulation of cell division. Phosphorylation at T790 or S375 significantly affects the catalytic activity of ECT2. This affinity-purified antibody has been tested for use in ELISA, western blot and immunoprecipitation. Specific conditions for reactivity should be optimized by the end user. Expect a band approximately 101 kDa in size by western blotting in the appropriate cell lysate or extract. Less than 2% reactivity is observed against the non-phosphorylated form of the immunizing peptide. This antibody is believed to be phospho specific for ECT2 phosphorylated at the pT790 residue. Experiments to generate more conclusive evidence are currently under preparation.